Systemic lupus erythematosus
Drug research and approvals for systemic lupus erythematosus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 288 studies of systemic lupus erythematosus are recruiting on ClinicalTrials.gov, Health Canada has authorized 29 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 288
- Trials authorized in Canada: 29
- FDA orphan approvals: 0
- EU medicines: 2
- Dual-targeting of B & T Cell Pathways Evaluation TrialNCT07946367 · Phase 1 / Phase 2 · Diabetes Free, Inc. · starts Dec 1, 2026
- ^68Ga-grazytracer PET for In Vivo Visualization of Immune Cell Effector FunctionsNCT07935174 · Not applicable · Peking University Third Hospital · starts Jun 1, 2026
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus StudyNCT07913919 · Not applicable · University of Cambridge · starts Nov 28, 2025
- Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus ErythematosusNCT07902622 · Not reported · Foundation University Islamabad · starts Mar 1, 2025
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusNCT07881120 · Phase 2 / Phase 3 · Beeline Medicines Corporation · starts Nov 3, 2026
- CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus ErythematosusNCT07855302 · Phase 1 · Seoul National University Hospital · starts Sep 14, 2026
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease…NCT07840287 · Phase 3 · EMD Serono Research & Development Institute, Inc. · starts Oct 22, 2026
- F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus ErythematosusNCT07829614 · Phase 1 · Shandong New Time Pharmaceutical Co., LTD · starts Oct 30, 2025
Approved 5
- BelimumabTumor necrosis factor ligand superfamily member 13B inhibitor
- AnifrolumabInterferon-alpha/beta receptor alpha chain antagonist
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 3 12 of 28
- EpratuzumabCD22 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- BlisibimodTumor necrosis factor ligand superfamily member 13B inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Prasterone
- AzathioprineAmidophosphoribosyltransferase inhibitor
- CholecalciferolVitamin D receptor agonist
- CenerimodSphingosine 1-phosphate receptor Edg-1 modulator
- Telitacicept
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- AldesleukinInterleukin-2 receptor agonist
- TabalumabTumor necrosis factor ligand superfamily member 13B inhibitor
Phase 2 12 of 66
- SifalimumabInterferon alpha inhibitor
- CyclophosphamideDNA inhibitor
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- AtaciceptTumor necrosis factor ligand superfamily member 13B inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- SolcitinibTyrosine-protein kinase JAK1 inhibitor
- CravacitinibTyrosine-protein kinase TYK2 negative allosteric modulator
- LeflunomideDihydroorotate dehydrogenase inhibitor
- RamiprilAngiotensin-converting enzyme inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- UpadacitinibTyrosine-protein kinase TYK2 inhibitor
- AspirinCyclooxygenase inhibitor
Phase 1 or earlier 12 of 32
- AMG-557ICOS ligand inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- Fludarabine
- MeloxicamCyclooxygenase-2 inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
- OmalizumabIg epsilon chain C region inhibitor
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- ClopidogrelPurinergic receptor P2Y12 antagonist
- FamotidineHistamine H2 receptor antagonist
- RosuvastatinHMG-CoA reductase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- MSC-2364447Tyrosine-protein kinase BTK inhibitor
How its trials ended
967 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 228 whose ending is known, 39% met their primary endpoint, 11% missed it and 50% stopped early.
- Completed, result not reported31633%
- Ongoing28930%
- Status unknown13414%
- Met its primary endpoint909%
- Stopped: other or unclear586%
- Missed its primary endpoint242%
- Stopped: enrollment or feasibility232%
- Stopped: sponsor or business decision172%
- Stopped: lack of efficacy121%
- Stopped: safety2<1%
- Stopped: funding2<1%
| Jan 20, 2026 | Multinational, interventional, 52-week, open-label, single-arm study to evaluate the treatment outcomes of anifrolumab 120 mg subcutaneous once weekly in…Anifrolumab (MEDI-546) | AstraZeneca Pharmaceuticals | Ongoing |
| Dec 23, 2025 | Phase 1b/2 study of AZD0120, a chimeric antigen receptor T-cell (car t) therapy targeting CD19 and B-cell maturation antigen (BCMA) in subjects with refractory…AZD0120 (GC012F) | AstraZeneca Pharmaceuticals | Pending |
| Aug 1, 2025 | A phase 2, multicenter, open-label study of CC-97540 (BMS-986353), CD19-targeted nex-t car t cells, in participants with active SLE (including lupus nephritis)…BMS-986353 (CC-97540) | Bristol-Myers Squibb | Ongoing |
| Dec 17, 2024 | A phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus…YTB323 (rapcabtagene autoleucel) / Fludarabine phosphate / Cyclophosphamide | Novartis Pharmaceuticals | Pending |
| Nov 14, 2024 | A phase I study to evaluate the safety and preliminary efficacy of ATA3219, allogeneic anti CD19 chimeric antigen receptor t cell (car t) therapy, in subjects…ATA3219 / Fludarabine phosphate / Cyclophosphamide / Methylprednisolone sodium… | Atara Biotherapeutics | Pending |
| Sep 13, 2024 | A phase 1 study to evaluate the efficacy and safety of AB-101, an allogeneic cord blood derived nk-cell therapy in combination with B-cell depleting mab in…AB-101 / Truxima (rituximab) / Gazyvaro (obinutuzumab) | Artiva Biotherapeutics | Pending |
| Feb 12, 2024 | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus…Ianalumab (VAY736) | Novartis Pharmaceuticals | Ongoing |
| Oct 25, 2023 | A phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-6194 in adult participants with systemic…MK-6194 | Merck & Co. (MSD) | Ongoing |
| Jun 29, 2023 | A phase III, randomized, double-blind, parallel-group, placebo controlled study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of iv…Saphnelo | AstraZeneca Pharmaceuticals | Ongoing |
| Feb 9, 2023 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of deucravacitinib in participants with active systemic lupus…Deucravacitinib (BMS-986165) | Bristol-Myers Squibb | Ongoing |
| Feb 9, 1999 | Humanized MAb (IDEC-131) to CD40LTreatment of systemic lupus erythematosus. | Biogen IdecInc. | Designated |
| Feb 18, 1998 | Recombinant humanized monoclonal antibody 5c8Treatment of systemic lupus erythematosus. | Biogen, Inc. | Designated |
| Jul 13, 1994 | DehydroepiandrosteroneTreatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients. | GlaxoSmithKline | Designated |
| Feb 14, 2022 | SaphneloAnifrolumab | AstraZeneca AB | EMA ↗ |
| Jul 13, 2011 | BenlystaBelimumab | GlaxoSmithKline (Ireland) Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA